correlated with the prognosis. Tumor size (P¼0.030), skip N2 metastasis (P¼0.009), single station N2 metastasis (P¼0.01) and lymph node ratio (P<0.001) significantly impacted N2 Nonesmall cell lung cancer prognosis. Cox regression analysis confirmed that tumor size (P¼0.017) and lymph node ratio (P¼0.010) were the independent prognosis factors. The 5 year over survival was 70.1% for the low risk group with tumor size less than 3cm and lymph node ratio less than 0.19. However, the 5 year over survival of high risk group with tumor size more than 3cm and lymph node ratio more than 0.19 was 24.5%, which was significantly different with the low risk group(P<0.001). Conclusion: Lymph node ratio and tumor size were the independent prognosis factors for N2 Nonesmall cell lung cancer fulfilling NCCN resection criteria, the risking groups based on lymph node ratio and tumor size can be better to predict the prognosis of N2 nonesmall cell lung cancer. Keywords: Lymph node ratio, Prognosis, NCCN resection criteria, N2 nonesmall cell lung cancer P28 Background: The recommended dose for erlotinib of 150 mg was developed based on the maximum tolerated dose (MTD); meanwhile the suggested dose for gefitinib is only one third of its MTD. Studies suggest that the optimal biologic dose of erlotinib should be lower and dependent of the body mass index. Hereby we present results and toxicity with 75 mg/day dose in Chilean patients. Method: We performed a retrospective review of patients with histologically proven (+) EGFR (+) mutation mNSCLC treated with 75mg/day erlotinib as starting dose at Centro Internacional de Estudios Clinicos Bradford Hill, Santiago, Chile. Clinical information, including toxicity grade 1-4, drug discontinuation, clinical evolution and radiological evaluation and overall survival were revised. Results: Patients received 75mg/day of erlotinib as starting dose. Sixteen (89%) patients were treated in first and two (11%) in second line treatment. Mean age was 62 years (range 36-89 years) and 50% patients were female. 16% patients had brain metastases at first diagnosis. 2 patients were tested for T790 mutation positive. 38% of patients had smoking history. All patients had mutation positive EGFR, 12 (66 %) had Del19 and 6 (34%) exon 21 mutation. Median progression free survival was 18 and overall survival 23 months. The main grade 1-2 toxicities were rash (33%) and diarrhea (25%). No grade 3-4 toxicity and no cases of drug discontinuation were reported. Conclusion: In South American population with mutated mNSCLC, a dose of 75mg/day of erlotinib was well tolerated. This dose resulted in comparable benefits in PFS and OS when compared to those reported in the literature with the standard dose. Genetic polymorphism in metabolic enzymes and lower body mass index could explain the same efficacy at lower dose. More studies are needed to explore the use of adjusted doses of biological agents in different ethnic backgrounds. Keyword: lung cancer, EGFR, Erlotinib, TKI
Background: The recommended dose for erlotinib of 150 mg was developed based on the maximum tolerated dose (MTD); meanwhile the suggested dose for gefitinib is only one third of its MTD. Studies suggest that the optimal biologic dose of erlotinib should be lower and dependent of the body mass index. Hereby we present results and toxicity with 75 mg/day dose in Chilean patients. Method: We performed a retrospective review of patients with histologically proven (+) EGFR (+) mutation mNSCLC treated with 75mg/day erlotinib as starting dose at Centro Internacional de Estudios Clinicos Bradford Hill, Santiago, Chile. Clinical information, including toxicity grade 1-4, drug discontinuation, clinical evolution and radiological evaluation and overall survival were revised. Results: Patients received 75mg/day of erlotinib as starting dose. Sixteen (89%) patients were treated in first and two (11%) in second line treatment. Mean age was 62 years (range 36-89 years) and 50% patients were female. 16% patients had brain metastases at first diagnosis. 2 patients were tested for T790 mutation positive. 38% of patients had smoking history. All patients had mutation positive EGFR, 12 (66 %) had Del19 and 6 (34%) exon 21 mutation. Median progression free survival was 18 and overall survival 23 months. The main grade 1-2 toxicities were rash (33%) and diarrhea (25%). No grade 3-4 toxicity and no cases of drug discontinuation were reported. Conclusion: In South American population with mutated mNSCLC, a dose of 75mg/day of erlotinib was well tolerated. This dose resulted in comparable benefits in PFS and OS when compared to those reported in the literature with the standard dose. Genetic polymorphism in metabolic enzymes and lower body mass index could explain the same efficacy at lower dose. More studies are needed to explore the use of adjusted doses of biological agents in different ethnic backgrounds. Background: In this study, we analyzed and compared the various toxicities presented by patients who performed immune therapy with diagnosis of lung cancer (LC) against other tumors in advanced stages, based on the knowledge of the greater number of comorbidities that patients with PC have in relationship to other tumors. The comorbidities associated with LC are the set of alterations and disorders that may be associated, for one reason or another, with this disease. The most prevalent comorbidities are severe smoking, hypertension, diabetes and is chemic heart disease, followed by COPD, asthma and anemia. Regarding immune therapy, we can say that it is a type of treatment designed to stimulate the body's natural defenses in order to fight cancer. Primary Objective: To compare the most frequent toxicities in patients diagnosed with lung cancer vs other types of tumors (kidney cancer, melanoma, gastric cancer, and mesothelioma) in stage IV, in treatment with immune therapy. Method: A retrospective observational descriptive study, 58 medical charts of patients of the Instituto Oncologico de Cordoba were analyzed. All patients received immune therapy. Two groups were selected; the first one was diagnosed with lung cancer and in the second group other types of tumors, both with stage IV pathologies. The entire study population was evaluated for PDL-1 before starting treatment, by IHC. Results: We included 58 patients, 33 patients (57%) had lung cancer and 25 (43%) had other types of tumors. When analyzing the toxicities of both groups it was observed that, the patients with lung cancer showed: Asthenia 20 patients (44%), Skin Rash 8 patients (18%), Diarrhea 3 patients (7%), hypothyroidism 2 patients (5%), liver toxicity 6 patients (13%) and hematological toxicity 6 patients (13%). In the second group patients exhibited: Asthenia 17 patients (61%), Skin Rash 4 patients (14%), Diarrhea 2 patients (7%), hypothyroidism 2 patients (7%) and hematological toxicity 3 patients (11%). Conclusion: In this work, we can observe that in both groups there were expected toxicities. The most frequent one was asthenia, but the group with lung cancer showed greater hepatic and hematological toxicity with a significant difference compared to other tumors. Keywords: immune therapy, toxicities, lung cancer compared other tumors, Lung cancer
